.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Predict branded drug patent expiration
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Argus Health
Harvard Business School
McKesson
Teva
Healthtrust
Cerilliant
Mallinckrodt
US Department of Justice
Federal Trade Commission

Generated: July 23, 2017

DrugPatentWatch Database Preview

Ondansetron - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for ondansetron and what is the scope of ondansetron patent protection?

Ondansetron
is the generic ingredient in nine branded drugs marketed by Sun Pharm Inds Ltd, Chartwell Molecules, Teva, Nesher Pharms, Midatech Pharma Us, Mylan, Sandoz, Glenmark Generics, Sun Pharm Inds, Aurobindo Pharma, Novartis Pharms Corp, Barr, Aurobindo Pharma Ltd, Glaxosmithkline, Apotex, Taro, Qilu Pharm Co Ltd, West-ward Pharms Int, Pliva Hrvatska Doo, Taro Pharms Ireland, Lannett, Wockhardt, Emcure Pharms, Gland Pharma Ltd, Sandoz Inc, Luitpold, Hospira, Silarx, Apotex Inc, Mylan Labs Ltd, Accord Hlthcare, Emcure Pharms Ltd, Hikma Intl Pharms, Sun Pharm Inds (in), Natco Pharma Ltd, Fresenius Kabi Usa, Ipca Labs Ltd, Sagent Pharms, Hikma Farmaceutica, Amneal Pharms, Dr Reddys Labs Ltd, and Claris, and is included in eighty-four NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ondansetron has fourteen patent family members in ten countries.

There are twenty-eight drug master file entries for ondansetron. Thirty-five suppliers are listed for this compound. There are three tentative approvals for this compound.

Summary for Generic Name: ondansetron

Tradenames:9
Patents:3
Applicants:42
NDAs:84
Drug Master File Entries: see list28
Suppliers / Packagers: see list35
Bulk Api Vendors: see list77
Clinical Trials: see list366
Patent Applications: see list7,447
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:ondansetron at DailyMed

Pharmacology for Ingredient: ondansetron

Tentative approvals for ONDANSETRON

Applicant Application No. Strength Dosage Form
► Subscribe► SubscribeEQ 2MG BASE/MLINJECTABLE;INJECTION
► Subscribe► SubscribeEQ 2MG BASE/MLINJECTABLE;INJECTION
► Subscribe► Subscribe4MGTABLET, ORALLY DISINTEGRATING;ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp
ZOFRAN
ondansetron hydrochloride
TABLET;ORAL020103-001Dec 31, 1992ABRXYesNo► Subscribe► Subscribe
Aurobindo Pharma Ltd
ONDANSETRON HYDROCHLORIDE
ondansetron hydrochloride
INJECTABLE;INJECTION202599-001Dec 21, 2012APRXNoNo► Subscribe► Subscribe
Midatech Pharma Us
ZUPLENZ
ondansetron
FILM;ORAL022524-002Jul 2, 2010RXYesYes8,580,830► SubscribeY ► Subscribe
Teva
ONDANSETRON HYDROCHLORIDE
ondansetron hydrochloride
TABLET;ORAL076252-002Jun 25, 2007ABRXNoNo► Subscribe► Subscribe
Gland Pharma Ltd
ONDANSETRON HYDROCHLORIDE
ondansetron hydrochloride
INJECTABLE;INJECTION090648-001Jun 15, 2012APRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: ondansetron

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp
ZOFRAN ODT
ondansetron
TABLET, ORALLY DISINTEGRATING;ORAL020781-001Jan 27, 19996,063,802*PED► Subscribe
Novartis Pharms Corp
ZOFRAN ODT
ondansetron
TABLET, ORALLY DISINTEGRATING;ORAL020781-002Jan 27, 19994,695,578*PED► Subscribe
Novartis Pharms Corp
ZOFRAN ODT
ondansetron
TABLET, ORALLY DISINTEGRATING;ORAL020781-001Jan 27, 19994,695,578*PED► Subscribe
Novartis Pharms Corp
ZOFRAN ODT
ondansetron
TABLET, ORALLY DISINTEGRATING;ORAL020781-002Jan 27, 19994,753,789*PED► Subscribe
Novartis Pharms Corp
ZOFRAN ODT
ondansetron
TABLET, ORALLY DISINTEGRATING;ORAL020781-001Jan 27, 19995,578,628*PED► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: ondansetron

Country Document Number Estimated Expiration
Canada2664986► Subscribe
European Patent Office2248519► Subscribe
European Patent Office2444072► Subscribe
South Korea20090080037► Subscribe
BrazilPI0719840► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Novartis
Moodys
UBS
Colorcon
Dow
US Army
Fuji
Federal Trade Commission
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot